OPKO Health, Inc. Equity Method Investment, Underlying Equity in Net Assets
OPKO Health, Inc. (OPK) had Equity Method Investment, Underlying Equity in Net Assets of $0 as of 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Notes › Investments › Equity Method Investments and Joint Ventures
us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets · last filed 2026-08-28
- 2026-06-30: Equity Method Investment, Underlying Equity in Net Assets $0.00.
- 2026-03-31: Equity Method Investment, Underlying Equity in Net Assets $2.53M.
- 2025-12-31: Equity Method Investment, Underlying Equity in Net Assets $1.55M.
- 2025-09-30: Equity Method Investment, Underlying Equity in Net Assets $1.44M.
| Period end | Equity Method Investment, Underlying Equity in Net Assets |
|---|---|
| 2026-06-30 | $0.00 10-Q/A · filed 2026-08-28 |
| 2026-03-31 | $2.53M 10-Q/A · filed 2026-08-28 |
| 2025-12-31 | $1.55M 10-Q/A · filed 2026-08-28 |
| 2025-09-30 | $1.44M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $1.59M 10-Q · filed 2025-07-31 |
| 2024-12-31 | $1.33M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.78M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $2.65M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $2.73M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $2.94M 10-Q · filed 2024-11-07 |
| 2023-09-30 | $2.35M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $2.62M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $3.34M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $4.12M 10-K · filed 2024-03-01 |
| 2022-09-30 | $2.62M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $4.82M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $4.50M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $3.58M 10-K · filed 2023-02-27 |
| 2021-09-30 | $9.05M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $2.24M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $2.48M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $2.25M 10-K · filed 2022-03-01 |
| 2020-09-30 | $2.37M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $2.37M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $1.43M 10-Q · filed 2020-05-06 |
| 2019-09-30 | $10.27M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $10.62M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $9.76M 10-Q · filed 2019-05-08 |
| 2018-09-30 | $20.05M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $15.55M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $23.59M 10-Q · filed 2018-05-08 |
| 2017-09-30 | $23.91M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $26.42M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $23.69M 10-Q · filed 2017-05-10 |
| 2016-09-30 | $33.54M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $16.25M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $22.11M 10-Q · filed 2016-05-09 |
| 2015-09-30 | $30.72M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $23.73M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $19.05M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $30.79M 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |